01
Dec
2008
Posted in I - Series C, Q - 3Q08, R - WEST, X - Diabetes, X - Metabolism
InteKrin Therapeutics (Los Altos, CA) clinical-stage biopharmaceutical company focused on the development of products for diabetes, metabolism and obesity, closed a $20M Series C financing. Participants include Skyline Ventures, Sofinnova Ventures, OrbiMed Advisors, , Sears Capital Management and Vivo Ventures.